Credit Suisse analyst Matt Miksic started coverage of Organogenesis with an Outperform rating and a $9 price target. The analyst notes that the company has assembled an "impressive" portfolio of regenerative medicine and differentiated products in key growth segments within wound care. His positive view is based on a clear opportunity to gain share in the high-value, high-growth amniotic tissue segment; sustainable double-digit growth, adjusting for upcoming reimbursement changes; and improving margins driven by mix and improving operating leverage.

BTIG notes that seven Medicare Administrative Contractors, or MACs - CGS, WPS, NGS, Palmetto, Novitas, First Coast, and Noridian - this morning published new proposed local coverage determinations, or LCDs, regarding the coverage of skin substitutes grafts and cellular and tissue based products for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. This marks "the second attempt in the past 12 months where MACs have proposed an LCD that would drastically shake up the advanced wound care market," says the analyst, who highlights that the proposed LCD includes non-coverage products from Integra Lifesciences (IART), Organogenesis (ORGO), Smith & Nephew (SNN), MiMedx (MDXG), Anika Therapeutics (ANIK) and numerous smaller, private wound care companies. The firm adds that it thinks Integra and Organogenesis both have meaningful exposure to the LCDs based on their product portfolio and the revenue mix within their Advanced Wound Care businesses.